Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

Petrylak, Daniel; de Wit, Ronald; Chi, Kim; Drakaki, Alexandra; Sternberg, Cora; Nishiyama, Hiroyuki; Castellano, Daniel; Hussain, Syed; Flechon, Aude; Bamias, Aristotelis; Yu, Evan; van der Heijden, Michiel; Matsubara, Nobuaki; Alekseev, Boris; Necchi, Andrea; Geczi, Lajos; Ou, Yen-Chuan; COŞKUN, HASAN; Su, Wen-Pin; Bedke, Jens; Gakis, Georgios; Percent, Ivor; Lee, Jae-Lyun; Tucci, Marcello; Semenov, Andrey; Laestadius, Fredrik; Peer, Avivit; Tortora, Giampaolo; Safina, Sufia; Garcia del Muro, Xavier; Rodriguez-Vida, Alejo; ÇİÇİN, İRFAN; HARPUTLUOĞLU, HAKAN; Tagawa, Scott; Vaishampayan, Ulka; Aragon-Ching, Jeanny; Hamid, Oday; Liepa, Astra; Wijayawardana, Sameera; Russo, Francesca; Walgren, Richard; Zimmermann, Annamaria; Hozak, Rebecca; Bell-McGuinn, Katherine; Powles, Thomas

doi:10.1016/s1470-2045(19)30668-0

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

Atıf İçin Kopyala

Petrylak D. P., de Wit R., Chi K. N., Drakaki A., Sternberg C. N., Nishiyama H., ...Daha Fazla

LANCET ONCOLOGY, cilt.21, sa.1, ss.105-120, 2020 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 21 Sayı: 1
Basım Tarihi: 2020
Doi Numarası: 10.1016/s1470-2045(19)30668-0
Dergi Adı: LANCET ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, MEDLINE
Sayfa Sayıları: ss.105-120
İnönü Üniversitesi Adresli: Evet

Özet

Background Ramucirumab-an IgG1 vascular endothelial growth factor receptor 2 antagonistplus docetaxel was previously reported to improve progression-free survival in platinum-refractory, advanced urothelial carcinoma. Here, we report the secondary endpoint of overall survival results for the RANGE trial.